Je was op zoek naar: biotehnoloških (Sloveens - Engels)

navodilo za delovanje biotehnoloških laboratorijev.
guidance for biotechnology laboratory operations

varnost nanotehnoloških in biotehnoloških proizvodov;
the safety of nanotechnology-based and biotechnology-based products;

zdravila, izdelana po enem od naslednjih biotehnoloških postopkov:
medicinal products developed by means of one of the following biotechnological processes:

zdravila, ki so izdelana po enem od naslednjih biotehnoloških postopkov:
medicinal products developed by means of one of the following biotechnological processes:

razvoj biotehnoloških procesov in njihova uporaba v industriji nista optimalna.
the development of biotechnology processes and their uptake by the industry are not optimal.

varnost nanotehnoloških in biotehnoloških proizvodov ter dolgoročne posledice njihove uporabe;
the safety of nanotechnology-based and biotechnology-based products and the long-term impact of their use;

biotehnologija – vse države članice izvajajo zakonodajo eu o pravnem varstvu biotehnoloških izumov
biotechnology – all member states have implemented the eu legislation on the legal protection of biotechnological inventions

ustrezno je treba upoštevati posebni primer biotehnoloških raziskav s poreklom iz držav v razvoju.
due consideration should be given to the specific case of biotechnological research originating in developing countries.

komisiji je do zdaj uspelo ta spor ohraniti v okviru rednih pogovorov o biotehnoloških zadevah s tožniki.
the commission has managed to contain this dispute until now in the context of a regular dialogue on biotech issues with the complainants.

ker se na področju pravnega varstva biotehnoloških izumov zakoni in prakse posameznih držav članic razlikujejo;
whereas differences exist in the legal protection of biotechnological inventions offered by the laws and practices of the different member states;

evropska direktiva o pravnem varstvu biotehnoloških izumov3 iz leta 1998 omogoča patentno varstvo izumov, povezanih z rastlinami.
the 1998 eu biotech patents directive3 authorises patent protection for plant-related inventions.

(a) zdravila za uporabo v veterinarski medicini, razvita po enem od naslednjih biotehnoloških postopkov:
(a) veterinary medicinal products developed by means of one of the following biotechnological processes:

komisija preučuje možnost novih javno-zasebnih partnerstev v biotehnoloških industrijskih panogah, da se pospeši razvoj sektorja.
the commission is considering a new public-private partnership on bio-based industries to accelerate the development of the sector.

na žalost še vedno poročajo o zamudah pri prenosu direktive 98/44/es o pravnem varstvu biotehnoloških izumov.
regrettably, delays are still reported in the transposition of directive 98/44/ec on the legal protection of biotechnological inventions.

eeso podpira čimprejšnjo hitro izvedbo direktive o pravnem varstvu biotehnoloških izumov s strani držav članic, ker bodo sicer neskladnosti ovirale razvoj evropske biotehnične industrije.
the eesc supports the rapid implementation of the directive on the legal protection of biotechnological inventions by all member states as soon as possible given that non-compliance will impede the development of the european biotech industry.

(12) za zdravila za napredno zdravljenje morajo veljati enaka ureditvena načela, kot veljajo za druge vrste biotehnoloških zdravil.
(12) advanced therapy medicinal products should be subject to the same regulatory principles as other types of biotechnology medicinal products.

3direktiva evropskega parlamenta in sveta 98/44/es z dne 6. julija 1998 o pravnem varstvu biotehnoloških izumov (ul,
2directive 98/44/ec of the european parliament and of the council of 6 july 1998 on the legal protection of biotechnological inventions (oj 1998 l 213, p.

za mnoge grožnje zdravju niso na voljo ustrezna zdravila, razvoj pa je počasen zaradi pomanjkanja tržnih možnosti in posledičnega nezanimanja industrije, biotehnoloških podjetij in akademskih krogov za investiranje v razvoj takšnih izdelkov.
for many health threats, no adequate medicinal products are available, yet development has been slow, due to a lack of market prospects and consequent failure to attract sufficient interest on the part of industry, biotechnology undertakings and academia to invest in the development of such products.

morebitna ekonomska bremena za podjetja unije se lahko zmanjšajo z izkoriščanjem potenciala biotehnoloških procesov in bioloških izdelkov za zmanjšanje emisij co2, ki bodo po ocenah dosegle od 1 do 2,5 milijarde ton ekv. co2 na leto do leta 2030.
the possible economic burdens for union enterprises can be reduced by harnessing the potential of biotechnology processes and bio-based products to reduce co2 emissions, estimated to range from between 1 to 2,5 billion tonnes co2 equivalent per year by 2030.

procese "sledljivosti" po vsej proizvodni verigi, npr. v zvezi z gensko spremenjenimi organizmi, vključno s tistimi na podlagi nedavnih biotehnoloških dosežkov;
"traceability" processes all along the production chain, for instance relating to genetically modified organisms, including those based on recent biotechnology developments;